Format

Send to

Choose Destination
Dig Dis Sci. 2009 Feb;54(2):385-8. doi: 10.1007/s10620-008-0349-0. Epub 2008 Jun 18.

The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma.

Author information

1
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Key Lab of Combined Muti-Organ Transplantation, Ministry of Health, Zhejiang University, Hangzhou, 310003, China.

Abstract

BACKGROUND:

Many patients with hepatocellular carcinoma (HCC) who undergo liver transplantation (LT) subsequently develop tumor recurrence; this is the main factor affecting long-term survival after LT. Factors associated with tumor recurrence should be determined to improve the outcome of LT. The purpose of the study was to evaluate the value of alpha-fetoprotein (AFP) in forecasting tumor recurrence after LT for patients with HCC.

METHODS:

AFP data before and after LT for 97 patients with HCC who underwent LT in our center were analyzed retrospectively.

RESULTS:

The mean follow-up time was 17.1 +/- 2.1 months for all 97 patients, overall tumor recurrence rate was 32.9% (32/97), and mean recurrence time was 7.2 +/- 3.2 months. The most common tumor recurrence sites were liver, lung, skeleton, and other sites. Pre-transplant AFP levels >400 ng/ml were associated with higher tumor recurrence. Post-transplant AFP levels not decreasing to <or=20 ng/ml within 2 months were also indicative of higher risk of recurrence.

CONCLUSIONS:

Pre-transplant AFP and the dynamic change of AFP after LT were valuable in predicting tumor recurrence after LT for patients with HCC.

PMID:
18563566
DOI:
10.1007/s10620-008-0349-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center